Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358365 | 0.84 | ALDH1A1 (0.52) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL14910969 | 0.84 | KMT2A (0.54) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL11162210 | 0.83 | EGFR (0.61) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL20528292 | 0.83 | BACE1 (0.47) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL30503636 | 0.83 | EGFR (0.61) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL14756190 | 0.77 | TAAR1 (0.46) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL24207410 | 0.76 | EGFR (0.53) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL22520176 | 0.76 | CYP1A2 (0.57) | EGFRKDM4EKMT2AMAPTMEN1 | |
| SCHEMBL584342 | 0.76 | BACE1 (0.41) | KDM4EKMT2AALDH1A1POLBBACE1 | |
| SCHEMBL789944 | 0.76 | PDGFRB (0.39) | HSD17B10ADORA3KDRHPGDDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106916194-B | Novel ketolide derivative containing amino, preparation method and application | 北京理工大学 | 2020-05-08 | — | — | CN | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| CN-100460415-C | Ketolactones, their use and process for their preparation and pharmaceutical compositions containing them | ABBOTT LAB (US) | 2009-02-11 | — | — | CN | disclosed |
| US-6458771-B1 | SERIES OF KETOLIDE ANTIBACTERIALS IN THE MACROLIDE FAMILY, DRUGS AND INTERMEDIATES, ERYTHROMYCIN ANALOGUES USEFUL IN THE TREATMENT OF BACTERIAL AND PROTOZOAL INFECTIONS AND IN THE TREATMENT OF GASTRIC MOTILITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020119938-A1 | Macrolide antiinfective agents | CHU DANIEL (US) | 2002-08-29 | — | — | US | disclosed |
| US-6399582-B1 | GASTROINTESTINAL DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6395710-B1 | CONTROLLING INFECTIONS | KOSAN BIOSCIENCES, INC. | 2002-05-28 | — | — | US | disclosed |
| WO-2002032918-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1171446-A2 | MACROLIDE ANTIINFECTIVE AGENTS | Kosan Biosciences, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063224-A2 | MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| CN-1237183-A | 6-0-substituted ketolides with antibacterial activity | ABBOTT CO (US) | 1999-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119938-A1 | Macrolide antiinfective agents | MLNR, DOHH, NOP2 | EGFR 2321/4885KDM4E 1780/4885KMT2A 2043/4885 |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | EGFR 530/4885KDM4E 3573/4885KMT2A 3611/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | EGFR 932/4885KDM4E 3095/4885KMT2A 3261/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | EGFR 932/4885KDM4E 3095/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.